Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have earned an average rating of “Moderate Buy” from the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $44.10.

A number of equities research analysts recently weighed in on OLMA shares. Guggenheim lowered their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Wall Street Zen upgraded Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Friday, May 22nd. Finally, The Goldman Sachs Group cut their price target on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ OLMA opened at $11.91 on Monday. Olema Pharmaceuticals has a 1 year low of $4.37 and a 1 year high of $36.26. The firm’s 50 day moving average price is $12.17 and its 200 day moving average price is $18.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. The firm has a market cap of $1.04 billion, a P/E ratio of -5.90 and a beta of 2.00.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52). As a group, sell-side analysts anticipate that Olema Pharmaceuticals will post -2.22 earnings per share for the current year.

Institutional Trading of Olema Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC lifted its stake in shares of Olema Pharmaceuticals by 9,476.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after acquiring an additional 1,232 shares during the period. Torren Management LLC acquired a new position in shares of Olema Pharmaceuticals during the fourth quarter valued at approximately $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Olema Pharmaceuticals during the fourth quarter worth approximately $88,000. Nisa Investment Advisors LLC raised its holdings in Olema Pharmaceuticals by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after purchasing an additional 477 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Olema Pharmaceuticals by 44.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock worth $96,000 after purchasing an additional 1,169 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.